MedTrace Logo

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

NCT03191981 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-08-24

No results posted yet for this study

Summary

This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory multiple myeloma (MM) that have had at least 1 prior line of therapy

Conditions

  • Myeloma Multiple

Interventions

DRUG

Cyclophosphamide

Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

DRUG

Lenalidomide

Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

DRUG

Pembrolizumab

Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

Sponsors & Collaborators

  • Myeloma UK

    collaborator OTHER

  • Karyopharm Therapeutics Inc

    collaborator INDUSTRY

  • University of Leeds

    lead OTHER

Principal Investigators

  • Rakesh Popat · University College, London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2017-08-01
Completion
2017-08-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03191981 on ClinicalTrials.gov